
Pharmaceutical intermediates
Adagrasib Intermediates
13 pharmaceutical intermediates for Adagrasib. Indication: Colorectal Cancer; Non-Small Cell Lung Cancer.
About Adagrasib
- Originator
- Mirati Therapeutics Inc; Array Biopharma
- Indication
- Colorectal Cancer; Non-Small Cell Lung Cancer
- Approved Date
- 12/12/2022
- NCE Patent
- 12/12/2027
- DS/DP
- 05/17/2037
Available intermediates
13 intermediates currently listed for Adagrasib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (S)-2-(Piperazin-2-yl)acetonitrile dihydrochloride | 2158301-19-8 | / | / |
| sodium 2-fluoroacrylate | 74893-46-2 | / | / |
| 8-chloronaphthalen-1-amine | 59107-51-6 | / | / |
| methyl 1-(8-chloronaphthalen-1-yl)-3-oxopiperidine-4-carboxylate | 2898538-56-0 | / | / |
| 7-(8-chloronaphthalen-1-yl)-2-mercapto-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol | 2898538-57-1 | / | / |
| 1-Bromo-8-chloronaphthalene | 20816-79-9 | / | / |
| tert-butyl 2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate | 916420-27-4 | / | / |
| 7-Benzyl-2,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-d]pyriMidine | 1059735-34-0 | / | / |
| Ethyl N-benzyl-3-oxo-4-piperidine-carboxylate hydrochloride | 52763-21-0 | / | / |
| 7-(8-chloronaphthalen-1-yl)-2-(isopropylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol | 2898538-61-7 | / | / |
| (S)-7-(8-chloronaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol | 2408250-15-5 | / | / |
| 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile | 2206737-06-4 | / | / |
| 2-FLUOROACRYLIC ACID | 430-99-9 | / | / |
我们能如何帮助您?
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →